EFPIA anticounterfeiting pilot success could see industry recognise parallel traders as part of supply chain
This article was originally published in Scrip
Executive Summary
Mass serialisation is a viable way of strengthening the supply chain and protecting against counterfeit medicines, a pilot launched by the European Federation of Pharmaceutical Industries and Associations (EFPIA) has shown. Furthermore, roll-out of such a verification system could prompt industry to recognise parallel traders as part of the supply chain.
You may also be interested in...
Brazil Authorizes Oxford/AZ and Sinovac Vaccines
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
Success For Dutch Parallel Registration and Reimbursement Pilot
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
Constitutional Complaints In Germany Cast Doubt Over Fate Of UPC
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
Need a specific report? 1000+ reports available
Buy Reports